What Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Buy
56
BBC Quote, Financials, Valuation and Earnings
Last price:
$17.19
Seasonality move
:
6%
Day range:
$17.45 - $18.10
52-week range:
$13.42 - $31.65
Dividend yield:
1.36%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
53.1K
Avg. volume:
109.2K
1-year change:
-34.67%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$17.61 | -- | -- | -- | $0.24 | 1.36% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$7.71 | -- | -- | -- | $0.00 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$60.52 | -- | -- | -- | $0.03 | 0.07% | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
$82.75 | -- | -- | -- | $0.03 | 0.04% | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
$98.07 | -- | -- | -- | $0.04 | 0.33% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.283 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 2.176 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.183 | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | 1.636 | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | 1.308 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
|
XHE
SPDR S&P Health Care Equipment ETF
|
-- | -- | -- | -- | -- | -- |
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
Virtus LifeSci Biotech Clinical Trials ETF vs. Competitors
-
Which has Higher Returns BBC or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About BBC or GNOM?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is BBC or GNOM More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.050, which suggesting that the stock is 4.952% more volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.784%.
-
Which is a Better Dividend Stock BBC or GNOM?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.36%. Global X Genomics & Biotechnology ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or GNOM?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns BBC or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is BBC or PBE More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.050, which suggesting that the stock is 4.952% more volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.840, suggesting its less volatile than the S&P 500 by 15.98%.
-
Which is a Better Dividend Stock BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.36%. Invesco Biotechnology & Genome ETF offers a yield of 0.07% to investors and pays a quarterly dividend of $0.03 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or PBE?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
-
Which has Higher Returns BBC or XHE?
SPDR S&P Health Care Equipment ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat SPDR S&P Health Care Equipment ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- -
What do Analysts Say About BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Equipment ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than SPDR S&P Health Care Equipment ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than SPDR S&P Health Care Equipment ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 XHESPDR S&P Health Care Equipment ETF0 0 0 -
Is BBC or XHE More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.050, which suggesting that the stock is 4.952% more volatile than S&P 500. In comparison SPDR S&P Health Care Equipment ETF has a beta of 1.069, suggesting its more volatile than the S&P 500 by 6.861%.
-
Which is a Better Dividend Stock BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.36%. SPDR S&P Health Care Equipment ETF offers a yield of 0.04% to investors and pays a quarterly dividend of $0.03 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Equipment ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or XHE?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Equipment ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than SPDR S&P Health Care Equipment ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Equipment ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for SPDR S&P Health Care Equipment ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- XHESPDR S&P Health Care Equipment ETF-- -- -- --
-
Which has Higher Returns BBC or XHS?
SPDR S&P Health Care Services ETF has a net margin of -- compared to Virtus LifeSci Biotech Clinical Trials ETF's net margin of --. Virtus LifeSci Biotech Clinical Trials ETF's return on equity of -- beat SPDR S&P Health Care Services ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- -
What do Analysts Say About BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand SPDR S&P Health Care Services ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus LifeSci Biotech Clinical Trials ETF has higher upside potential than SPDR S&P Health Care Services ETF, analysts believe Virtus LifeSci Biotech Clinical Trials ETF is more attractive than SPDR S&P Health Care Services ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 XHSSPDR S&P Health Care Services ETF0 0 0 -
Is BBC or XHS More Risky?
Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.050, which suggesting that the stock is 4.952% more volatile than S&P 500. In comparison SPDR S&P Health Care Services ETF has a beta of 1.046, suggesting its more volatile than the S&P 500 by 4.633%.
-
Which is a Better Dividend Stock BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF has a quarterly dividend of $0.24 per share corresponding to a yield of 1.36%. SPDR S&P Health Care Services ETF offers a yield of 0.33% to investors and pays a quarterly dividend of $0.04 per share. Virtus LifeSci Biotech Clinical Trials ETF pays -- of its earnings as a dividend. SPDR S&P Health Care Services ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBC or XHS?
Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues are --, which are smaller than SPDR S&P Health Care Services ETF quarterly revenues of --. Virtus LifeSci Biotech Clinical Trials ETF's net income of -- is lower than SPDR S&P Health Care Services ETF's net income of --. Notably, Virtus LifeSci Biotech Clinical Trials ETF's price-to-earnings ratio is -- while SPDR S&P Health Care Services ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus LifeSci Biotech Clinical Trials ETF is -- versus -- for SPDR S&P Health Care Services ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -- XHSSPDR S&P Health Care Services ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Which Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Is Gartner a Safe Stock to Own?
Gartner (NYSE:IT) is among the world’s largest consulting, research and…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
70
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 44x
Alerts
Buy
57
RGC alert for May 14
Regencell Bioscience Holdings [RGC] is up 8.9% over the past day.
Buy
54
HALO alert for May 14
Halozyme Therapeutics [HALO] is down 4.72% over the past day.
Buy
91
COIN alert for May 14
Coinbase Global [COIN] is up 2.36% over the past day.
